title: Combined carboplatin plus ifosfamide and cisplatin in patients with advanced ovarian carcinoma. A phase I-II study. GOCS (Gynecological Oncology Cooperative Study).
abstract: Because of the relative lack of overlapping toxicity, carboplatin (PPL) and cisplatin (CDDP) can be easily combined for treatment of ovarian cancer to increase total platinum dose intensity. Ifosfamide (IFO), one of the most effective single agents in ovarian cancer, has a low hematological toxicity when administered in continuous infusion. From January 1991 to December 1993, 34 patients with advanced ovarian cancer, previously untreated with chemo- or radiotherapy, were enrolled in a phase I-II study with the aim of determining the maximum tolerated dose (MTD) of CDDP (on day 8 of a 28-day cycle) in combination with PPL (300 mg/m2 on day 1) and IFO (4,000 mg/m2/24 h by continuous infusion on day 1). The initial dose level of CDDP was 40 mg/m2, which was continuously increased by 10 mg/m2 up to the MTD defined as one dose level below that inducing dose-limiting toxicity (DLT) in at least two-thirds of treated patients; no dose escalation was allowed in the same patient. Grade 3-4 leukopenia and thrombocytopenia were observed in 54 and 49% of patients, respectively. The DLT was reached at 70 mg/m2 and therefore the dose recommended for the phase II study was 60 mg/m2. Complete (CR) plus partial response was observed in 88% of patients with a 21% pathological CR. With a minimum follow-up of 32 months (median 40 months), median progression-free survival and overall survival were 21 and 39 months, respectively. In conclusion, the combination of CDDP, PPL, and IFO provides an effective regimen for ovarian cancer with an acceptable toxicity profile.
authors.affiliation: Oncology Institute, Bari, Italy.
authors.forename: V
authors.initials: V
authors.lastname: Lorusso
authors.forename: B
authors.initials: B
authors.lastname: Leone
authors.forename: G
authors.initials: G
authors.lastname: Di Vagno
authors.forename: L
authors.initials: L
authors.lastname: Manzione
authors.forename: S
authors.initials: S
authors.lastname: Palmeri
authors.forename: C
authors.initials: C
authors.lastname: Vallejo
authors.forename: M
authors.initials: M
authors.lastname: Machiavelli
authors.forename: G
authors.initials: G
authors.lastname: Nacci
authors.forename: D
authors.initials: D
authors.lastname: Bilancia
authors.forename: V
authors.initials: V
authors.lastname: Leonardi
authors.forename: A
authors.initials: A
authors.lastname: Catino
authors.forename: G
authors.initials: G
authors.lastname: Gargano
authors.forename: G
authors.initials: G
authors.lastname: Loverro
authors.forename: L
authors.initials: L
authors.lastname: Selvaggi
authors.forename: M
authors.initials: M
authors.lastname: De Lena
mesh_terms: D000328:Adult; D000368:Aged; D018906:Antineoplastic Agents, Alkylating / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D016190:Carboplatin / Q000008:administration & dosage; D002277:Carcinoma / Q000188:drug therapy*; D002945:Cisplatin / Q000008:administration & dosage; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007069:Ifosfamide / Q000008:administration & dosage; D007970:Leukopenia / Q000139:chemically induced; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D016019:Survival Analysis; D013921:Thrombocytopenia / Q000139:chemically induced; D016896:Treatment Outcome
chemical_list: D018906:Antineoplastic Agents, Alkylating; D016190:Carboplatin; D002945:Cisplatin; D007069:Ifosfamide